Ad is loading...
CARM
Price
$0.88
Change
-$0.06 (-6.38%)
Updated
Nov 15 closing price
IOVA
Price
$8.18
Change
-$0.41 (-4.77%)
Updated
Nov 15 closing price
101 days until earnings call
Ad is loading...

CARM vs IOVA

Header iconCARM vs IOVA Comparison
Open Charts CARM vs IOVABanner chart's image
Carisma Therapeutics
Price$0.88
Change-$0.06 (-6.38%)
Volume$238.78K
CapitalizationN/A
Iovance Biotherapeutics
Price$8.18
Change-$0.41 (-4.77%)
Volume$17.44M
CapitalizationN/A
CARM vs IOVA Comparison Chart
Loading...
CARM
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
IOVA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
CARM vs. IOVA commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CARM is a Sell and IOVA is a Sell.

COMPARISON
Comparison
Nov 18, 2024
Stock price -- (CARM: $0.88 vs. IOVA: $8.18)
Brand notoriety: CARM and IOVA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CARM: 170% vs. IOVA: 295%
Market capitalization -- CARM: $36.87M vs. IOVA: $2.49B
CARM [@Biotechnology] is valued at $36.87M. IOVA’s [@Biotechnology] market capitalization is $2.49B. The market cap for tickers in the [@Biotechnology] industry ranges from $472.8B to $0. The average market capitalization across the [@Biotechnology] industry is $2.66B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CARM’s FA Score shows that 0 FA rating(s) are green whileIOVA’s FA Score has 0 green FA rating(s).

  • CARM’s FA Score: 0 green, 5 red.
  • IOVA’s FA Score: 0 green, 5 red.
According to our system of comparison, IOVA is a better buy in the long-term than CARM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CARM’s TA Score shows that 6 TA indicator(s) are bullish while IOVA’s TA Score has 6 bullish TA indicator(s).

  • CARM’s TA Score: 6 bullish, 4 bearish.
  • IOVA’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, both CARM and IOVA are a good buy in the short-term.

Price Growth

CARM (@Biotechnology) experienced а -12.55% price change this week, while IOVA (@Biotechnology) price change was -22.72% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.58%. For the same industry, the average monthly price growth was -5.90%, and the average quarterly price growth was -0.16%.

Reported Earning Dates

CARM is expected to report earnings on May 15, 2023.

IOVA is expected to report earnings on Feb 26, 2025.

Industries' Descriptions

@Biotechnology (-8.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IOVA($2.49B) has a higher market cap than CARM($36.9M). IOVA YTD gains are higher at: 0.615 vs. CARM (-69.857). CARM has higher annual earnings (EBITDA): -72.61M vs. IOVA (-418.89M). IOVA has more cash in the bank: 413M vs. CARM (40.4M). CARM has less debt than IOVA: CARM (8.17M) vs IOVA (81.7M). IOVA has higher revenues than CARM: IOVA (32.8M) vs CARM (20.7M).
CARMIOVACARM / IOVA
Capitalization36.9M2.49B1%
EBITDA-72.61M-418.89M17%
Gain YTD-69.8570.615-11,359%
P/E RatioN/AN/A-
Revenue20.7M32.8M63%
Total Cash40.4M413M10%
Total Debt8.17M81.7M10%
FUNDAMENTALS RATINGS
CARM vs IOVA: Fundamental Ratings
CARM
IOVA
OUTLOOK RATING
1..100
5622
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
49
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9896
PRICE GROWTH RATING
1..100
8759
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IOVA's Valuation (49) in the Biotechnology industry is somewhat better than the same rating for CARM (94) in the null industry. This means that IOVA’s stock grew somewhat faster than CARM’s over the last 12 months.

IOVA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CARM (100) in the null industry. This means that IOVA’s stock grew similarly to CARM’s over the last 12 months.

IOVA's SMR Rating (96) in the Biotechnology industry is in the same range as CARM (98) in the null industry. This means that IOVA’s stock grew similarly to CARM’s over the last 12 months.

IOVA's Price Growth Rating (59) in the Biotechnology industry is in the same range as CARM (87) in the null industry. This means that IOVA’s stock grew similarly to CARM’s over the last 12 months.

IOVA's P/E Growth Rating (100) in the Biotechnology industry is in the same range as CARM (100) in the null industry. This means that IOVA’s stock grew similarly to CARM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CARMIOVA
RSI
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
81%
Momentum
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
88%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
84%
Advances
ODDS (%)
Bullish Trend 12 days ago
83%
Bullish Trend 11 days ago
83%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
85%
Aroon
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
84%
View a ticker or compare two or three
Ad is loading...
CARM
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
IOVA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FAUFX47.160.66
+1.42%
Fidelity Advisor Utilities M
COIIX16.96-0.06
-0.35%
Calvert International Opportunities I
BRKIX13.93-0.05
-0.36%
MFS Blended Research Em Mkts Eq I
DDVRX18.67-0.09
-0.48%
Delaware Value® R
RNWBX76.10-0.76
-0.99%
American Funds New World R2

CARM and

Correlation & Price change

A.I.dvisor indicates that over the last year, CARM has been loosely correlated with PRME. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if CARM jumps, then PRME could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CARM
1D Price
Change %
CARM100%
-5.93%
PRME - CARM
40%
Loosely correlated
-6.95%
BEAM - CARM
37%
Loosely correlated
-8.59%
ARDX - CARM
36%
Loosely correlated
+5.52%
ABCL - CARM
35%
Loosely correlated
-3.99%
IOVA - CARM
35%
Loosely correlated
-4.77%
More

IOVA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IOVA has been loosely correlated with CRSP. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if IOVA jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IOVA
1D Price
Change %
IOVA100%
-4.77%
CRSP - IOVA
46%
Loosely correlated
+0.85%
BEAM - IOVA
45%
Loosely correlated
-8.59%
VCYT - IOVA
43%
Loosely correlated
-2.97%
VTGN - IOVA
43%
Loosely correlated
-3.66%
CYTK - IOVA
42%
Loosely correlated
-8.19%
More